← Browse by Condition
Medical Condition
gastric adenocarcinoma
Total Trials
13
Recruiting Now
13
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for gastric adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — gastric adenocarcinoma Clinical Trials
How many clinical trials are currently recruiting for gastric adenocarcinoma?
ClinicalMetric currently tracks 13 actively recruiting clinical trials for gastric adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 13. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for gastric adenocarcinoma?
gastric adenocarcinoma research spans Phase 1 (3 trials), Phase 2 (6 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a gastric adenocarcinoma clinical trial?
Eligibility criteria for gastric adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 6
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07714538
Recruiting
Enrollment
1,000 pts
Location
United Kingdom
Sponsor
Imperial College London
NCT07464756 Phase 2
Recruiting
Enrollment
80 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT07263386 Phase 2
Recruiting
Enrollment
460 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT06798376
Recruiting
Enrollment
300 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT07284186 Phase 1
Recruiting
Enrollment
155 pts
Location
United States
Sponsor
Plexium, Inc.
NCT07334431 Phase 1, Phase 2
Recruiting
Enrollment
45 pts
Location
China
Sponsor
Henan Cancer Hospital
NCT07001592 Phase 1
Recruiting
Enrollment
18 pts
Location
United States
Sponsor
Allegheny Singer Research Inst...
NCT07007182 Phase 2
Recruiting
Enrollment
54 pts
Location
China
Sponsor
Jinbo Yue
NCT06038578 Phase 2
Recruiting
Enrollment
146 pts
Location
United States, Japan...
Sponsor
Toray Industries, Inc
NCT06881043
Recruiting
Enrollment
300 pts
Location
China
Sponsor
The First Hospital of Jilin Un...
NCT05059444
Recruiting
Enrollment
2,020 pts
Location
United States, Franc...
Sponsor
Guardant Health, Inc.
NCT06943781
Recruiting
Enrollment
15,000 pts
Location
China
Sponsor
Fudan University
NCT07546812 Phase 2
Recruiting
Enrollment
120 pts
Location
United States, Austr...
Sponsor
Gilead Sciences
Related Conditions
esophageal adenocarcinoma (2) gastric cancer (2) oesophageal squamous cell carcinoma (1) oesophageal adenocarcinoma (1) pancreatic ductal adenocarcinoma pdac (1) cholangiocarcinoma (1) hepatocellular carcinoma hcc (1) colorectal adenocarcinoma (1) esophageal squamous cell carcinoma (1) gastric squamous cell carcinoma (1) gastroesophageal junction gej adenocarcinoma (1) metastatic solid tumor (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology